Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06030011 · ClinicalTrials.gov registry record · NA

Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations

A NA study of Head and Neck Cancer, sponsored by The University of Texas Health Science Center, Houston.

Recruiting
Registry status
NA
Development phase
270
Enrollment target
5
Study locations

NCT06030011: Recruiting NA study of Head and Neck Cancer, sponsored by The University of Texas Health Science Center, Houston.

NCT06030011 is a NA study of Head and Neck Cancer that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 270 participants, roughly in line with the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target. The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06030011, a NA study of Head and Neck Cancer, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.

RECRUITING
Registry status
NA
Development phase
270 participants
Enrollment target
5
Study locations

Study Summary

The PI and the research team developed the New York University (NYU) Electronic Patient Visit Assessment (ePVA) for head and neck cancer (HNC) as a patient-reported outcome measure (PRO) for the early detection of uncontrolled symptoms. The ePVA is digital patient-reported symptom monitoring system, providing actionable information at point-of-care that enables clinicians to provide real-time interventions. The study aims to advance the science of cancer care delivery by testing the effectiveness of the ePVA as a digital patient-reported monitoring system for patients with HNC in real-world settings and identify implementation strategies that optimize the effectiveness of the ePVA in diverse rural and urban settings. The study hypothesis is that participants assigned to the ePVA arm will have better swallowing, taste and smell, and social function than participants assigned to usual care arm at 4 weeks after completing radiation therapy.

Primary Outcome

The EORTC QLQ-C30 and QLQ-H\&N35 will be used to measure head and neck cancer symptoms, such as social function, senses of taste and smell, and swallowing. The scores will be summed and then transformed to a single score ranging from 0=Best to 100=Worst.

Conditions Studied

Interventions

  • BEHAVIORAL Usual Care
  • BEHAVIORAL NYU Electronic Patient Visit Assessment (ePVA)

Study Locations (5)

New York

  • NYU Meyers College of Nursing - New York
  • NYU Langone Perlmutter Cancer Center - New York

Kansas

  • University of Kansas Cancer Center - Kansas City

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Texas

  • UTHealth Houston Cizik School of Nursing - Houston

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2024-06-25
Est. Completion 2028-08-31
Phase NA

What NCT06030011 shows while recruiting

NCT06030011 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target.

The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.

NCT06030011 lists 5 locations in 4 states (New York, Kansas, Pennsylvania).

Frequently Asked Questions

What is clinical trial NCT06030011 about?

NCT06030011 is a clinical study titled "Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations". The PI and the research team developed the New York University (NYU) Electronic Patient Visit Assessment (ePVA) for head and neck cancer (HNC) as a patient-reported outcome measure (PRO) for the early detection of uncontrolled symptoms. The ePVA is digital patient-reported symptom monitoring system,...

What is the current status of trial NCT06030011?

This trial is currently recruiting. It is a NA study. The enrollment target is 270 participants. The study started on 2024-06-25. Estimated completion is 2028-08-31.

What conditions does trial NCT06030011 study?

This clinical trial studies the following conditions: Head and Neck Cancer.

What interventions are being tested in trial NCT06030011?

The interventions under investigation include: Usual Care (BEHAVIORAL), NYU Electronic Patient Visit Assessment (ePVA) (BEHAVIORAL).

Who is sponsoring clinical trial NCT06030011?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06030011 being conducted?

This trial has 5 study locations across Kansas, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06030011's enrollment target sits among peer trials

270 41st of 250 higher than 210 of 250 other Head and Neck Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00801489 · 270 participants · Phase 2

    Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • NCT04372485 · 270 participants · NA

    Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents

  • NCT04528446 · 270 participants

    The Impact of Glomerular Disorders on Bone Quality and Strength

  • NCT05215327 · 270 participants · Phase 2

    High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06030011, the US trial registry maintained by the National Library of Medicine. NCT06030011 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.